How Does Ocaliva Compare to Newer PBC Treatments?

If your doctor has mentioned Ocaliva (obeticholic acid) for your primary biliary cholangitis (PBC), it is helpful to know how it compares to newer medications that have recently become available. These medications are typically used as add-on therapies, meaning you take them alongside your current ursodeoxycholic acid (UDCA), unless you are completely intolerant to UDCA ^[1].

Ocaliva is a well-known second-line option for lowering liver enzymes, but its ability to prevent severe long-term liver damage has recently been questioned following its confirmatory clinical trial (the COBALT trial) ^[2]. This has led to intense regulatory scrutiny. Meanwhile, the landscape of PBC treatment is evolving rapidly, and newer drugs—specifically seladelpar (Livdelzi) and elafibranor (Iqirvo)—offer different ways to manage the condition and its symptoms ^[3].

How They Work

Ocaliva belongs to a class of drugs called FXR agonists (farnesoid X receptor agonists) ^[4]. It works by mimicking a natural acid in your liver to help reduce the production of bile acids and improve the flow of bile out of the liver, reducing liver damage ^[4].

In contrast, both seladelpar and elafibranor belong to a different class of medications known as PPAR agonists (peroxisome proliferator-activated receptor agonists) ^[5][6]. While they also help reduce bile acid toxicity and inflammation, they target entirely different receptors in the liver cells to achieve this effect ^[6]. This difference in mechanism is responsible for the variations in side effects and symptom management between the medications.

The Impact on Itching (Pruritus) and Fatigue

For many patients, the two most debilitating symptoms of PBC are intense itching and profound fatigue. How these drugs affect your daily symptoms is a major factor in choosing between them.

Ocaliva is known to frequently cause or worsen itching ^[7][1]. In long-term studies, up to 70% of patients taking Ocaliva reported itching as a side effect ^[8]. For some patients, this worsening of symptoms is severe enough that they must stop taking the medication ^[9].

The newer treatments offer a much better outlook:

• Seladelpar (Livdelzi): This is currently the only second-line therapy shown in clinical trials to actively reduce the severity of itching ^[10]. Furthermore, it is the first to demonstrate significant improvements in fatigue, particularly by reducing itch-related sleep disturbances ^[10].
• Elafibranor (Iqirvo): While elafibranor has not been shown to significantly reduce itching compared to a placebo, it importantly does not carry the high risk of making it worse, unlike Ocaliva ^[11].

Side Effects Comparison

While the newer medications avoid the severe itching associated with Ocaliva, they are not side-effect free. Both seladelpar and elafibranor are generally well-tolerated, but they do have potential adverse effects.

Safety Considerations in Advanced Liver Disease

Safety in advanced stages of PBC is another critical distinction. Ocaliva is strictly contraindicated (should not be used) in patients who have advanced or decompensated cirrhosis (liver scarring with complications) ^[2]. It is also unsafe for patients with compensated cirrhosis who show signs of portal hypertension (increased pressure in the vein leading to the liver), such as fluid in the abdomen or enlarged veins in the esophagus ^[2]. This is because Ocaliva has been linked to severe liver injury and liver failure in these specific groups.

The long-term safety of seladelpar and elafibranor in patients with advanced cirrhosis is still being established ^[14]. If you have advanced liver disease, any second-line medication requires careful consideration and close monitoring by a hepatologist. Close monitoring typically means more frequent blood tests to check your liver enzymes and routine FibroScans to measure liver stiffness.